Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Talquetamab + daratumumab for relapsed/refractory myeloma in TRIMM-2 study shows ORR 71.4% (QW cohort) and 82.4% (Q2W); median PFS 23.3 and 21.2 mos; most common AEs = oral and skin events, CRS, infections; grade 3/4 in 81.5%.”
Title: Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 study
Authors: Ajai Chari, Niels W.C.J. van de Donk, Bhagirathbhai Dholaria, Katja C Weisel, Maria-Victoria Mateos, Hartmut Goldschmidt, Tom G Martin, Daniel Morillo, Donna Reece, Paula Rodriguez-Otero, Manisha Bhutani, Anita D’Souza, Albert Oriol, Laura Rosiñol, Nizar J. Bahlis, Deeksha Vishwamitra, Sheri Skerget, Raluca I. Verona, Kalpana K Bakshi, Lijuan Kang, Thomas J Prior, Lien Vandenberk, Jaszianne Tolbert, Sangmin Lee, Damiette Smit, Ralph Wäsch
You can read the Full Article in Blood.
You can find more posts featuring Robert Orlowski on OncoDaily.
